A randomized multicenter study on ambulatory blood pressure and arterial stiffness in patients treated with valsartan/amlodipine or nifedipine GITS.


Journal

Journal of clinical hypertension (Greenwich, Conn.)
ISSN: 1751-7176
Titre abrégé: J Clin Hypertens (Greenwich)
Pays: United States
ID NLM: 100888554

Informations de publication

Date de publication:
02 2019
Historique:
received: 16 08 2018
revised: 05 10 2018
accepted: 23 10 2018
pubmed: 26 12 2018
medline: 17 6 2020
entrez: 25 12 2018
Statut: ppublish

Résumé

In a pre-specified subgroup analysis of a 12-week randomized multicenter study, we investigated effects of valsartan/amlodipine 80/5 mg single-pill combination (n = 75) and nifedipine GITS 30 mg (n = 75) on ambulatory blood pressure (BP) and arterial stiffness assessed by brachial-ankle pulse wave velocity (PWV) in patients with uncontrolled hypertension. At week 12, the between-treatment mean differences in systolic/diastolic BP were smaller for 24-hour and daytime (-2.1/-1.7 and -2.0/-1.5 mm Hg, respectively, P ≥ 0.22) but greater (P < 0.01) for nighttime (-4.0/-2.8 mm Hg, P ≤ 0.09), especially in sustained uncontrolled hypertension (-5.0/-4.1 mm Hg, P ≤ 0.04) and non-dippers (-6.5/-3.7 mm Hg, P ≤ 0.07), in favor of valsartan/amlodipine. At week 12, PWV was significantly reduced from baseline by valsartan/amlodipine (n = 59, P < 0.0001) but not nifedipine (n = 59, P = 0.06). The changes in PWV were significantly associated with that in ambulatory systolic BP and pulse pressure in the nifedipine (P ≤ 0.0008) but not valsartan/amlodipine group (P ≥ 0.57), with a significant interaction (P ≤ 0.045). The valsartan/amlodipine combination was more efficacious than nifedipine GITS in lowering nighttime BP in sustained uncontrolled hypertension and non-dippers, and in lowering arterial stiffness independent of BP lowering.

Identifiants

pubmed: 30582271
doi: 10.1111/jch.13457
pmc: PMC8030622
doi:

Substances chimiques

Amlodipine, Valsartan Drug Combination 0
Nifedipine I9ZF7L6G2L

Types de publication

Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

252-261

Commentaires et corrections

Type : CommentIn

Informations de copyright

©2018 Wiley Periodicals, Inc.

Références

Hypertension. 2010 Jun;55(6):1314-22
pubmed: 20404219
Lancet. 2005 Sep 10-16;366(9489):895-906
pubmed: 16154016
Lancet. 2005 Sep 10-16;366(9489):907-13
pubmed: 16154017
J Hypertens. 2013 Aug;31(8):1537-8
pubmed: 23822927
Hypertension. 2013 Oct;62(4):719-25
pubmed: 23959555
Hypertension. 2014 Dec;64(6):1388-98
pubmed: 25245386
Vasc Health Risk Manag. 2013;9:95-104
pubmed: 23662062
Hypertens Res. 2002 May;25(3):359-64
pubmed: 12135313
J Hypertens. 2003 May;21(5):821-48
pubmed: 12714851
J Hypertens. 2018 Oct;36(10):1953-2041
pubmed: 30234752
Hypertens Res. 2003 Aug;26(8):609-14
pubmed: 14567499
Curr Med Res Opin. 2010 Jul;26(7):1705-13
pubmed: 20469975
Korean Circ J. 2016 Mar;46(2):222-8
pubmed: 27014353
J Clin Hypertens (Greenwich). 2019 Feb;21(2):252-261
pubmed: 30582271
J Clin Hypertens (Greenwich). 2017 Dec;19(12):1319-1326
pubmed: 29106031
Adv Ther. 2013 Aug;30(8):771-83
pubmed: 23963546
Adv Ther. 2018 Mar;35(3):353-366
pubmed: 29498018
Am J Hypertens. 2004 Nov;17(11 Pt 1):1050-5
pubmed: 15533733
J Hum Hypertens. 2006 Oct;20(10):787-94
pubmed: 16810279
Kardiol Pol. 2015;73(9):768-80
pubmed: 25987296
Science. 1991 Jun 28;252(5014):1813-6
pubmed: 2063193
Curr Med Res Opin. 2015 Dec;31(12):2287-96
pubmed: 26397178
Hypertension. 2014 May;63(5):958-67
pubmed: 24446059
Kidney Int. 2011 Mar;79(5):555-62
pubmed: 21107446
Hypertension. 2018 Jun;71(6):1269-1324
pubmed: 29133354
Turk Kardiyol Dern Ars. 2016 Jul;44(5):404-13
pubmed: 27439926
N Engl J Med. 2008 Dec 4;359(23):2417-28
pubmed: 19052124
J Clin Hypertens (Greenwich). 2017 Oct;19(10):973-982
pubmed: 28560779

Auteurs

Shao-Kun Xu (SK)

Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Qi-Fang Huang (QF)

Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Wei-Fang Zeng (WF)

Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Chang-Sheng Sheng (CS)

Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Yan Li (Y)

Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Ji-Guang Wang (JG)

Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH